<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>biotech industry on FinanClub</title>
    <link>https://finan.club/tags/biotech-industry/</link>
    <description>Recent content in biotech industry on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 10 Jan 2024 09:03:07 +0000</lastBuildDate><atom:link href="https://finan.club/tags/biotech-industry/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>TGTX</title>
      <link>https://finan.club/us/tgtx/</link>
      <pubDate>Wed, 10 Jan 2024 09:03:07 +0000</pubDate>
      
      <guid>https://finan.club/us/tgtx/</guid>
      <description>score:343
Chances: TG Therapeutics, Inc. has entered into an agreement to acquire a worldwide license to Precision BioSciences, Inc.&amp;rsquo;s Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseases. The average of price targets set by Wall Street analysts indicates a potential upside of 127.</description>
    </item>
    
  </channel>
</rss>
